JAK1 and myelofibrosis: CYT387 is an orally available, potent small molecule inhibitor of the JAK1/2 pathway currently undergoing Phase I/II clinical trials for the treatment of myelofibrosis, a frequently diagnosed fatal myeloproliferative disorder (36).